BRCA1 and ovarian cancer: In the phase II study involving 32 patients with germline BRCA1/2 mutant platinum-sensitive ovarian cancer, the disease control rate (DCR) at 12 weeks was 81%, and the objective response rate (ORR) was 63%, with acceptable toxicity (85).